SUGAR LAND, TX (July 14, 2017) – Gram-positive osteomyelitis was successfully treated with telavancin, as published in an article in The International Journal of Antimicrobial Agents. Primary author was Claudia P. Schroeder, Clinical Research Lead at Healix®, in...
SUGAR LAND, TX (March 20, 2017) – Healix has been selected among an exclusive number of distributers to become a national provider of Cuvitru [Immune Globulin Subcutaneous (Human)] 20%. Immunologists who partner with Healix receive a collection of clinical and...
SUGAR LAND, TX (May 23, 2016) – Dalbavancin is a long-acting lipoglycopeptide, approved for the treatment of acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria. A retrospective study was conducted of 105 patients treated...
SUGAR LAND, TX (January 25, 2016) – Pediatric outpatient antimicrobial therapy (OPAT) is increasing, however, data on management, safety, and clinical outcomes are limited. A two-year retrospective, observational study was conducted of 64 pediatric patients receiving...
SAN DIEGO, CA (October 10, 2015) – Septicemia constitutes a major cause for 30-day hospital readmissions and is the most expensive condition treated in U.S. hospitals according to the Agency for Healthcare Research and Quality, Healthcare Cost, and Utilization...
PHILADELPHIA, PA (October 10, 2014) – Outpatient antimicrobial therapy (OPAT) provided by a physician office infusion center revealed an overall low 30-day hospital admission rate of 6.8% compared to 26% previously reported. This collaborative, retrospective study...
![Healix® is Now a National Provider of Cuvitru® [Immune Globulin Subcutaneous (Human)] 20%](https://healix.net/wp-content/uploads/pic-cuvitru.jpg)
Recent Comments